EMA says Gilead's Zydelig can stay on the market after trial deaths by Carly Helfand Monday, July 11, 2016 Gilead cancer drug Zydelig--flagged earlier this year after serious adverse events cropped up in studies--can stay on the market with some new recommendations, European regulators have concluded.
